MXCT News and Press, MaxCyte Inc. From 03/15/23

2023-03-15 21:41:02 ET MaxCyte, Inc. (MXCT) Q4 2022 Earnings Conference Call March 15, 2023 16:30 ET Company Participants Sean Menarguez - Investor Relations Doug Doerfler - President and Chief Executive Officer Ron Holtz - Interim Chief Financial Officer C...

2023-03-15 16:11:09 ET MaxCyte press release ( NASDAQ: MXCT ): Q4 GAAP EPS of -$0.05 beats by $0.02 . Revenue of $10.88M (+7.2% Y/Y) misses by $2.25M . Initial 2023 guidance for total revenue growth of 21% to 26% over 2022, including core revenue growth of 20% ...

ROCKVILLE, Md., March 15, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innova...

ROCKVILLE, Md., March 08, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to supp...

2023-03-06 18:12:13 ET MaxCyte ( NASDAQ: MXCT ) on Monday announced expectations for Q4 and FY 2022 revenue that came in below estimates. The company said it anticipated Q4 revenue to be about $12.4M, compared to a consensus figure of $13.14M. FY 2022 revenue is ex...

Full year 2022 total revenue expected to be approximately $44.3 million, representing growth of 31% over full year 2021 Fourth quarter 2022 total revenue expected to be approximately $12.4 million, representing growth of 22% over fourth quarter 2021 Installed base at year end 2022...

ROCKVILLE, Md., Feb. 01, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovati...

Summary BAMCO’s 13F portfolio value decreased from $31.14B to $30.95B this quarter. Ron Baron decreased Rivian Automotive and Alphabet during the quarter. Their top five positions are at ~31% of the overall portfolio. This article is part of a series that provides an on...

ROCKVILLE, Md., Jan. 03, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company providing enabling platform technologies to advance innovative cell-based research, as well as next-generation cell therapeutic discovery, development and...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Although a new year tends to bring feelings of optimism, when it comes to the current market dynamics, it’s time to consider hot stocks to book profits in before 2023 arrives. At first, circumstances appeared favorable, ...